🚀 VC round data is live in beta, check it out!
Galecto Valuation Multiples
Discover revenue and EBITDA valuation multiples for Galecto and similar public comparables like Tsumura, Innoviva, ANI Pharmaceuticals, Organon and more.
Galecto Overview
About Galecto
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Founded
2019
HQ
Employees
5
Website
Sectors
Financials (LTM)
EV
$2B
Galecto Financials
Galecto reported last 12-month revenue of — and negative EBITDA of ($198M).
In the same LTM period, Galecto generated — in gross profit, ($198M) in EBITDA losses, and had net loss of ($181M).
Revenue (LTM)
Galecto P&L
In the most recent fiscal year, Galecto reported revenue of — and net income of —.
Galecto expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($198M) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($181M) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Galecto Stock Performance
Galecto has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Galecto's stock price is $29.69.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGalecto Valuation Multiples
Galecto trades at (9.0x) EV/EBITDA.
EV / Revenue (LTM)
Galecto Financial Valuation Multiples
As of April 10, 2026, Galecto has market cap of $2B and EV of $2B.
Equity research analysts estimate Galecto's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Galecto has a P/E ratio of (9.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/EBITDA | (9.0x) | XXX | — | XXX | XXX | XXX |
| EV/EBIT | (9.7x) | XXX | — | XXX | XXX | XXX |
| P/E | (9.9x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Galecto Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Galecto Margins & Growth Rates
Galecto's revenue in the last fiscal year grew by —.
Galecto Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | (17%) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Galecto Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tsumura | XXX | XXX | XXX | XXX | XXX | XXX |
| Innoviva | XXX | XXX | XXX | XXX | XXX | XXX |
| ANI Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Organon | XXX | XXX | XXX | XXX | XXX | XXX |
| CStone Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Galecto M&A Activity
Galecto acquired XXX companies to date.
Last acquisition by Galecto was on XXXXXXXX, XXXXX. Galecto acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Galecto
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGalecto Investment Activity
Galecto invested in XXX companies to date.
Galecto made its latest investment on XXXXXXXX, XXXXX. Galecto invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Galecto
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Galecto
| When was Galecto founded? | Galecto was founded in 2019. |
| Where is Galecto headquartered? | Galecto is headquartered in Denmark. |
| How many employees does Galecto have? | As of today, Galecto has over 5 employees. |
| Who is the CEO of Galecto? | Galecto's CEO is Sherwin Sattarzadeh. |
| Is Galecto publicly listed? | Yes, Galecto is a public company listed on Nasdaq. |
| What is the stock symbol of Galecto? | Galecto trades under GLTO ticker. |
| When did Galecto go public? | Galecto went public in 2020. |
| Who are competitors of Galecto? | Galecto main competitors are Tsumura, Innoviva, ANI Pharmaceuticals, Organon. |
| What is the current market cap of Galecto? | Galecto's current market cap is $2B. |
| Is Galecto profitable? | No, Galecto is not profitable. |
| What is the current EBITDA of Galecto? | Galecto has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Galecto? | Current EBITDA multiple of Galecto is (9.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.